AB Soft The Brief Pain Inventory ii - Manual (Page 18)

31
Depressive Disorders
1. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin
JG, Schatzberg AF. Duloxetine 60 mg once-daily in the
treatment of painful physical symptoms in patients with major
depressive disorder. J Psychiatr Res 39(1): 43-53, 1/2005.
2. Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah
D, Raskin J, Petit C, Dernyttenaere K. Efficacy and safety of
duloxetine 60 mg once daily in the treatment of pain in
patients with major depressive disorder and at least moderate
pain of unknown etiology: A Randomized controlled trial.
Journal of Clinical Psychiatry 68(11): 1707-1716, 11/2007.
3. Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of
valdecoxib in the treatment of chronic low back pain: results
of a randomized, placebo-controlled trial. Clin Ther 26(8):
1249-1260, 8/2004.
4. Davison SN, Jhangri GS. The impact of chronic pain on
depression, sleep, and the desire to withdraw from dialysis in
hemodialysis patients. J Pain Symptom Manage 30(5): 465-
473, 11/2005.
5. Friedberg F, Quick J. Alexithymia in chronic fatigue syndrome:
associations with momentary, recall, and retrospective
measures of somatic complaints and emotions. Psychosom
Med 69(1): 54-60, 1/2007.
6. Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A,
Pereira D, St GD, Sonbolian N, Ronsaville D, Torvik S, Calis KA,
Phillips TM, Cizza G. Quality of life and pain in premenopausal
women with major depressive disorder: The POWER Study.
Health Qual Life Outcomes 4(1): 2, 1/2006.
7. O'Mahony S, Goulet J, Kornblith A, Abbatiello G, Clarke B,
Kless-Siegel S, Breitbart W, Payne R. Desire for hastened death,
cancer pain and depression: report of a longitudinal
observational study. J Pain Symptom Manage 2005;29:446-
457.Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and
aberrant drug-related behaviors in medically ill patients with
and without histories of substance abuse. Clin J Pain 22(2):
173-181, 2/2006.
32
8. Poleshuck EL, Giles DE, Tu X. Pain and depressive symptoms
among financially disadvantaged women's health patients. J
Womens Health (Larchmt ) 15(2): 182-193, 3/2006.
9. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K,
Jamison RN. Psychiatric History and Psychologic Adjustment
as Risk Factors for Aberrant Drug-related Behavior Among
Patients With Chronic Pain. Clin J Pain 23(4): 307-315, 5/2007.
10. Williams LS, Jones WJ, Shen J, Robinson RL, Kroenke K.
Outcomes of newly referred neurology outpatients with
depression and pain. Neurology 63(4): 674-677, 8/2004.
Fabry Disease
1. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG,
Kampmann C, Linhart A, Sunder-Plassmann G, Houge G,
Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects
of agalsidase alfa treatment. Eur J Clin Invest 34(12): 838-844,
12/2004.
2. Cleeland CS. Pain assessment: the advantages of using pain
scales in lysosomal storage diseases. Acta Paediatr Suppl
91(439): 43-47, 2002.
3. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA,
Kampmann C, Beck M. Natural history of Fabry disease in
females in the Fabry Outcome Survey. J Med Genet 43(4):
347-352, 4/2006.
4. Hoffmann B, Garcia de LA, Mehta A, Beck M, Widmer U, Ricci
R. Effects of enzyme replacement therapy on pain and health
related quality of life in patients with Fabry disease: data from
FOS (Fabry Outcome Survey). J Med Genet 42(3): 247-252,
3/2005.
5. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C,
Leon Leal JA, Santus F, Beck M. Enzyme replacement therapy
with agalsidase alfa in children with Fabry disease. Acta
Paediatr 96(1): 122-127, 1/2007.
6. Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer
F, Beck M. Use of gabapentin to reduce chronic neuropathic
pain in Fabry disease. J Inherit Metab Dis 26(4): 413-414, 2003.